Boothbay Fund Management’s Pacira BioSciences PCRX Stock Holding History

Boothbay Fund Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,816	Closed	-$433K	–	1987
2023 Q2	$433K	Buy	10,816 +5,061	+88%	+$209K	0.01%	1168
2023 Q1	$235K	Buy	+5,755	New	+$229K	﹤0.01%	1651
2020 Q3	–	Sell	-7,110	Closed	-$373K	–	1165
2020 Q2	$373K	Buy	+7,110	New	+$297K	0.03%	645
2017 Q3	–	Sell	-4,218	Closed	-$201K	–	738
2017 Q2	$201K	Buy	+4,218	New	+$196K	0.04%	566
2017 Q1	–	Sell	-10,078	Closed	-$1.47K	–	907
2016 Q4	$1.47K	Buy	+10,078	New	+$336K	0.34%	37

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Boothbay Fund Management's PCRX Position: Q3 2023 in Review

Boothbay Fund Management sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 10,816 shares — an estimated $433K sold.

Boothbay Fund Management first reported a position in PCRX in Q4 2016 and held it in 5 quarters. The position peaked at $433K in Q2 2023. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.

Boothbay Fund Management reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
Boothbay Fund Management sold 10,816 Pacira BioSciences shares in Q3 2023, an estimated $433K.
Boothbay Fund Management first reported a position in Pacira BioSciences in Q4 2016 and held it in 5 quarters.
Boothbay Fund Management's Pacira BioSciences position peaked at $433K in Q2 2023.
261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.

Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.